WALTHAM,
Mass., Dec. 8, 2022 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical-stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced that in
connection with the hiring, announced on December 5, 2022, of Steve M. Sabus as Chief Commercial Officer,
Mr. Sabus received an inducement award to purchase up to
220,000 shares of common stock. The stock option has an exercise
price per share of $25.44, the
closing price of the Company's common stock on the Nasdaq Global
Select Market on December 5, 2022 and
will vest over four years, with 25% of the underlying shares
vesting on the one-year anniversary of the vesting commencement
date and 1/48th of the underlying shares vesting monthly thereafter
over 36 months, subject to Mr. Sabus' continued service
relationship with Syndax through the applicable vesting dates.
Syndax's Board of Directors approved the award as inducement
material to Mr. Sabus' employment in accordance with NASDAQ
Listing Rule 5635(c)(4).
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies.
Highlights of the Company's pipeline include revumenib (SNDX-5613),
a highly selective inhibitor of the Menin–MLL binding interaction,
and axatilimab, a monoclonal antibody that blocks the colony
stimulating factor 1 (CSF-1) receptor, both currently in pivotal
trials. For more information, please
visit www.syndax.com or follow the Company
on Twitter and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-301698812.html
SOURCE Syndax Pharmaceuticals, Inc.